Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jun 1;38(16):1763-1773.
doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne  1 , Mustafa Suker  2 , Karin Groothuis  3 , Janine M Akkermans-Vogelaar  3 , Marc G Besselink  4 , Bert A Bonsing  5 , Jeroen Buijsen  6 , Olivier R Busch  4 , Geert-Jan M Creemers  7 , Ronald M van Dam  8 , Ferry A L M Eskens  9 , Sebastiaan Festen  10 , Jan Willem B de Groot  11 , Bas Groot Koerkamp  2 , Ignace H de Hingh  12 , Marjolein Y V Homs  9 , Jeanin E van Hooft  13 , Emile D Kerver  14 , Saskia A C Luelmo  15 , Karen J Neelis  16 , Joost Nuyttens  17 , Gabriel M R M Paardekooper  18 , Gijs A Patijn  19 , Maurice J C van der Sangen  20 , Judith de Vos-Geelen  21 , Johanna W Wilmink  22 , Aeilko H Zwinderman  22 , Cornelis J Punt  22 , Casper H van Eijck  2 , Geertjan van Tienhoven  1 ; Dutch Pancreatic Cancer Group
Affiliations
Clinical Trial

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne et al. J Clin Oncol. .

Abstract

Purpose: Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven.

Patients and methods: In this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery and 4 courses of adjuvant gemcitabine or to immediate surgery and 6 courses of adjuvant gemcitabine. The primary end point was overall survival by intention to treat.

Results: Between April 2013 and July 2017, 246 eligible patients were randomly assigned; 119 were assigned to preoperative chemoradiotherapy and 127 to immediate surgery. Median overall survival by intention to treat was 16.0 months with preoperative chemoradiotherapy and 14.3 months with immediate surgery (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P = .096). The resection rate was 61% and 72% (P = .058). The R0 resection rate was 71% (51 of 72) in patients who received preoperative chemoradiotherapy and 40% (37 of 92) in patients assigned to immediate surgery (P < .001). Preoperative chemoradiotherapy was associated with significantly better disease-free survival and locoregional failure-free interval as well as with significantly lower rates of pathologic lymph nodes, perineural invasion, and venous invasion. Survival analysis of patients who underwent tumor resection and started adjuvant chemotherapy showed improved survival with preoperative chemoradiotherapy (35.2 v 19.8 months; P = .029). The proportion of patients who suffered serious adverse events was 52% versus 41% (P = .096).

Conclusion: Preoperative chemoradiotherapy for resectable or borderline resectable pancreatic cancer did not show a significant overall survival benefit. Although the outcomes of the secondary end points and predefined subgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
CONSORT diagram. CRT, chemoradiotherapy; CT, computed tomography.
FIG 2.
FIG 2.
(A) Overall survival (OS), (B) disease-free survival (DFI), (C) locoregional failure–free interval (LFFI), and (D) distant metastasis–free interval (DMFI) in 246 patients randomly assigned to preoperative chemoradiotherapy (CRT; 119 patients) or immediate surgery (127 patients) according to intention-to-treat analysis. Tick marks indicate censored observations. HR, hazard ratio.
FIG 3.
FIG 3.
(A) Overall survival (OS), (B) disease-free survival (DFI), (C) locoregional failure–free interval (LFFI), and (D) distant metastasis–free interval (DMFI) in the 120 patients who had a resection of the tumor and started the postoperative chemotherapy and randomly assigned to preoperative chemoradiotherapy (CRT; 55 patients) or immediate surgery (65 patients). Tick marks indicate censored observations. HR, hazard ratio.
See this image and copyright information in PMC

Comment in

References

    1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011-1024, 2017 - PubMed
    1. Conroy T, Hammel P, Hebbar M, et al. : FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395-2406, 2018 - PubMed
    1. Bakens MJ, van der Geest LG, van Putten M, et al. : The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: A nationwide population-based analysis. Cancer Med 5:2825-2831, 2016 - PMC - PubMed
    1. Merkow RP, Bilimoria KY, Tomlinson JS, et al. : Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 260:372-377, 2014 - PubMed
    1. Mayo SC, Gilson MM, Herman JM, et al. : Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 214:33-45, 2012 - PMC - PubMed

Publication types

MeSH terms